NAD+

NAD+'s neurological relevance starts with how the compound reaches the central nervous system. Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. Direct blood-brain barrier transport is rarely the dominant route for peptide compounds; vagal-afferent gut-brain signalling and effects on cerebral vasculature where the barrier is locally compromised typically produce the CNS phenotype. The detail follows.

Pharmacokinetics and cognitive dose timing

The Hours; cellular pool dynamic half-life of NAD+ via iv/subq/intranasal/oral precursors (nr/nmn) administration sets the timing window for cognitive effects. At 100-1000 mg 1x weekly iv; daily subq at lower doses, receptor occupancy curves and CNS exposure align with the typical multi-week onset profile reported by cognitive-focused users. The standard 1x weekly iv; daily subq at lower doses dosing pattern is calibrated to maintain therapeutic exposure without continuous saturation, preserving the natural rhythm of the targeted system.

Inflammation and neurological recovery

One of the most replicated effects across compounds in NAD+'s class (Pyridine nucleotide cofactor) is reduction of inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues including the central nervous system. For users whose cognitive complaints track with chronic low-grade neuroinflammation — long-COVID, post-viral cognitive fog, post-concussion lingering symptoms, chronic stress — this anti-inflammatory layer is often the most operationally relevant mechanism. NAD+'s contribution operates on the same axis at 100-1000 mg per dose.

Cerebral perfusion and the structural cognitive substrate

Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. NAD+, with its Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The Hours; cellular pool dynamic pharmacokinetic profile supports this restorative rather than stimulant phenotype.

Dose timing for NAD+ is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

NAD+ stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.

• NAD+ + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with NAD+'s mechanism in cognitive / neurological protocols.
• NAD+ + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with NAD+'s mechanism in cognitive / neurological protocols.
• NAD+ + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with NAD+'s mechanism in cognitive / neurological protocols.
• NAD+ + DSIP: Mechanism remains incompletely characterised. Pairs naturally with NAD+'s mechanism in cognitive / neurological protocols.

Lens-specific safety considerations for cognitive / neurological use of NAD+: Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.